This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Women's Health  • Women's Health, Other  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Long-term Clinical Utility or Temporary Solution?

Charis Eng, MD, PhD; Dirk Iglehart, MD

JAMA. 2004;292:496-498.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Medical science is a victim of its own success. Clinical and translational investigation has resulted in a bounty of relevant and specialized knowledge that is adopted into routine clinical use. While this 21st-century science is hurtling quickly into the clinical arena, the relative growth of clinicians in some specialized areas, who are facile in using 21st-century scientific knowledge to practice 21st-century medicine, has not increased at a rate to keep pace with that of recent scientific advances. Compounded with the growing trend of viewing patients as partners in medical decision making, necessitating educating and helping patients with choices in a field that changes weekly, the medical community is facing a crisis. Two articles published in this issue of JAMA try to address this problem by exploring the utility and limitations of patient decision aids in breast cancer genetic risk assessment¹ and breast cancer . . . [Full Text of this Article]

Author Affiliations: Clinical Cancer Genetics Program, Human Cancer Genetics Program, Comprehensive Cancer Center, Division of Human Genetics, Department of Internal Medicine, Ohio State University, Columbus (Dr Eng); and Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, Cambridge, England (Dr Eng); Department of Cancer Biology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Department of Surgery, Harvard Medical School, Boston, Mass (Dr Iglehart).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?